Orchestra BioMed Holdings, Inc. - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
OBIO Nasdaq 3841 orchestrabiomed.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Orchestra BioMed Holdings, Inc.

Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT - Mar 3rd, 2026 6:00 am
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences - Feb 19th, 2026 6:00 am
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 13th, 2026 2:05 pm
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17% - Jan 22nd, 2026 4:17 am
Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics - Jan 12th, 2026 7:00 am
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs - Dec 31st, 2025 9:13 am
Favourable Signals For Orchestra BioMed Holdings: Numerous Insiders Acquired Stock - Dec 12th, 2025 3:33 am
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - Dec 8th, 2025 5:00 am
Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements - Nov 28th, 2025 11:25 pm
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates - Nov 10th, 2025 3:30 pm
Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates - Nov 10th, 2025 2:10 pm
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Nov 4th, 2025 8:00 am
Orchestra BioMed to Host Business Update Call on November 12, 2025 - Nov 3rd, 2025 6:00 am
The past five years for Orchestra BioMed Holdings (NASDAQ:OBIO) investors has not been profitable - Nov 1st, 2025 7:07 am
Canadian-Made Technology Gives Hospital Teams Clearer Images at the Bedside - Oct 30th, 2025 6:00 am
Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements - Oct 28th, 2025 6:00 am
Fixing fragmentation: Life Sciences Central launches to strengthen Canada's commercialization engine - Oct 27th, 2025 7:03 am
Orchestra BioMed Announces First Patients Enrolled in Virtue® SAB US Pivotal IDE Coronary Trial - Oct 27th, 2025 7:00 am
OBIO® Introduces the Future Female Leaders in Life Sciences - Oct 23rd, 2025 5:00 am
Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit - Oct 9th, 2025 6:00 am